PerpEquities

Equity · Healthcare

Novartis AG (NVS) perpetual futures

NVS perpetual futures on 1 crypto exchanges – live perp price vs the stock, funding rate, open interest and where to trade NVSUSDT.

Novartis AG develops, manufactures, and markets healthcare products, focusing on innovative prescription medicines for oncology, immunology, neuroscience, and cardiovascular diseases.

$160.41+0.4%NYSE closed
Open in terminal

Price chart

Not enough price history yet for this newly listed market.

Use the left and right arrow keys to inspect points on the chart.

Collecting venue price data...
venue perp mark · Bitget (NVS/USDT)
Auto: highest-volume live perp venueOpen in TradingView

Trading data

Perpetual market activity

1/2 live markets
Venues
2
Live markets
1/2
24h volume
$21.6K
Open interest
$4.4K
Best liquidity
$908.4K
Bitget
Tightest spread
+11.2 bps
Bitget
Highest volume
$21.6K
Bitget
Settlement mix
USDT · 2/2
Perp/spot vol.
0.00x
Spot volume $393.5M
OI / float
0.00%
Float $293.6B
Spot performance
1D+0.39%
5D+5.55%
1M+6.41%
6M-1.25%
YTD+18.29%
1Y+27.00%

Venue matrix

2 markets

Some venue links are sponsored. We may receive a commission, and eligible users may occasionally receive trading-fee discounts, at no additional cost to you.

Trade
BitgetTradeNVS/USDTTrading$160.410.0% APR
0.000% every 8h
+11.2 bps$908.4K$21.6K$4.4KUSDT20x
BingXTradeNVS-USDTWatchlist------USDT-

Embed this asset

NVS perpetuals · perpequities.comNVS perpetuals · perpequities.com
<a href="https://perpequities.com/stocks/nvs-perp"><img src="https://perpequities.com/badge/nvs-perp.svg" width="240" height="64" alt="NVS perpetuals · perpequities.com" loading="lazy"></a>

Tradability

Execution quality

Thin liquidity · 1 of 1 venues absorb $10k · Typical cost: +12.5 bps

Cheapest execution: Bitget · +12.5 bps

Taker execution estimate incl. approx. fees - maker fills are not guaranteed.

Best venues for this underlying

Best liquidity

NVS

Tightest spread

NVS

Highest volume

NVS

Funding history

Stored venue snapshots by market

Company data

Company fundamentals

Updated 5h ago
Market cap
$310B
Updated 5h ago
Revenue
$55.6B
Trailing 12 months
Revenue growth
+4%
Next fiscal year
Profit margin
+23.1%
P/E
24.7
Peer P/E 29.8
Free cash flow
$15.8B
Trailing 12 months
More metrics
Net income
$12.8B
Trailing 12 months
P/S
5.6
Peer P/E
29.8
Similar listed perps
Revenue estimate
$57.1B
Next fiscal year
Earnings
2026-10-27
Revenue est. $14.6B · Updated 5h ago
Dividend
$4.74
2026-03-11

Fundamental detail

Annual + quarterly
Latest revenue$54.8B
Net margin+25.6%
Free cash flow$17.7B
Net debt$25.6B
2020$49.9B
2021$44B
2022$43.5B
2023$46.7B
2024$51.7B
2025$54.8B
PeriodRevenueGrowthNet incomeFCF
2020$49.9B+3%$8.1B$11.1B
2021$44B-12%$24B$12.5B
2022$43.5B-1%$7B$12B
2023$46.7B+7%$14.9B$11.7B
2024$51.7B+11%$11.9B$13.8B
2025$54.8B+6%$14.1B$17.7B
PeriodGross marginOperating marginNet marginROEROA
2020+69.7%+20.3%+16.2%+14.3%+6.1%
2021+73.3%+22.9%+54.6%+35.5%+18.2%
2022+73.4%+18.3%+16.0%+11.7%+5.9%
2023+73.3%+20.9%+31.8%+31.8%+14.9%
2024+75.2%+28.1%+23.1%+27.1%+11.7%
2025+75.0%+31.2%+25.6%+30.5%+12.2%
PeriodCashDebtNet debtCurrent ratio
2020$9.7B$37.9B$28.2B0.90
2021$12.4B$31B$18.6B1.51
2022$7.5B$27.9B$20.4B1.29
2023$13.4B$26.3B$13B1.16
2024$11.5B$31.3B$19.8B1.04
2025$11.4B$37B$25.6B1.12
PeriodMarket capEnterprise valueP/SP/E
2020$203.5B$231.7B4.125.2
2021$185.6B$204.2B4.27.7
2022$187.3B$207.6B4.326.9
2023$209.8B$222.7B4.514.1
2024$196.4B$216.2B3.816.4
2025$267.3B$292.9B4.919.0
Q3 2024$13.2B
Q4 2024$13.6B
Q1 2025$13.6B
Q2 2025$14.8B
Q3 2025$14.4B
Q4 2025$13.3B
Q1 2026$13.5B
Q2 2026$14.4B
PeriodRevenueGrowthNet incomeFCF
Q3 2024$13.2B+9%$3.2B$5.5B
Q4 2024$13.6B+15%$2.8B$3.1B
Q1 2025$13.6B+12%$3.6B$2.2B
Q2 2025$14.8B+15%$4B$6.1B
Q3 2025$14.4B+9%$3.9B$5.7B
Q4 2025$13.3B-2%$2.4B$1.6B
Q1 2026$13.5B-1%$3.2B$2.9B
Q2 2026$14.4B-3%$3.3B$5.6B
PeriodGross marginOperating marginNet marginROEROA
Q3 2024+75.4%+27.5%+24.2%+7.4%+3.1%
Q4 2024+75.5%+26.0%+20.8%+6.4%+2.8%
Q1 2025+76.3%+34.2%+26.5%+9.4%+3.6%
Q2 2025+77.6%+32.8%+27.2%+9.6%+3.9%
Q3 2025+75.4%+31.3%+27.4%+8.9%+3.7%
Q4 2025+73.4%+26.4%+18.1%+5.2%+2.1%
Q1 2026+74.4%+31.3%+23.3%+8.2%+2.7%
Q2 2026+74.5%+32.8%+22.7%+7.9%+2.7%
PeriodCashDebtNet debtCurrent ratio
Q3 2024$13.6B$32.2B$18.6B1.11
Q4 2024$11.5B$31.3B$19.8B1.04
Q1 2025$7.1B$31.3B$24.2B0.79
Q2 2025$6.7B$32.6B$26B0.82
Q3 2025$9.6B$32B$22.5B0.88
Q4 2025$11.4B$37.1B$25.7B1.12
Q1 2026$6.9B$47B$40.1B0.85
Q2 2026$7.6B$49B$41.4B0.86
PeriodMarket capEnterprise valueP/SP/E
Q3 2024$231.4B$250B17.618.2
Q4 2024$193.4B$213.2B14.317.1
Q1 2025$219.4B$243.6B16.115.2
Q2 2025$235.7B$261.7B15.914.6
Q3 2025$239B$261.5B16.615.2
Q4 2025$263.7B$289.4B19.827.4
Q1 2026$291.6B$331.7B21.623.1
Q2 2026$298.6B$339.9B20.722.9
Historical value series
Revenue
Q3 2023: $12.1BQ4 2023: $11.8BQ1 2024: $12.1BQ2 2024: $12.9BQ3 2024: $13.2BQ4 2024: $13.6BQ1 2025: $13.6BQ2 2025: $14.8BQ3 2025: $14.4BQ4 2025: $13.3BQ1 2026: $13.5BQ2 2026: $14.4BQ3 2023Q2 2026
Net income
Q3 2023: $1.8BQ4 2023: $8.5BQ1 2024: $2.7BQ2 2024: $3.2BQ3 2024: $3.2BQ4 2024: $2.8BQ1 2025: $3.6BQ2 2025: $4BQ3 2025: $3.9BQ4 2025: $2.4BQ1 2026: $3.2BQ2 2026: $3.3BQ3 2023Q2 2026
EBITDA
Q3 2023: $4.9BQ4 2023: $4.2BQ1 2024: $4.7BQ2 2024: $5.2BQ3 2024: $5.6BQ4 2024: $5.2BQ1 2025: $5.8BQ2 2025: $6.1BQ3 2025: $5.8BQ4 2025: $5.1BQ1 2026: $5.4BQ2 2026: $5.9BQ3 2023Q2 2026
Free cash flow
Q3 2023: $5.3BQ4 2023: $2.1BQ1 2024: $1.1BQ2 2024: $4.1BQ3 2024: $5.5BQ4 2024: $3.1BQ1 2025: $2.2BQ2 2025: $6.1BQ3 2025: $5.7BQ4 2025: $1.6BQ1 2026: $2.9BQ2 2026: $5.6BQ3 2023Q2 2026
EPS
Q3 2023: $0.85Q4 2023: $4.11Q1 2024: $1.31Q2 2024: $1.59Q3 2024: $1.57Q4 2024: $1.41Q1 2025: $1.82Q2 2025: $2.06Q3 2025: $2.02Q4 2025: $1.25Q1 2026: $1.65Q2 2026: $1.71Q3 2023Q2 2026
Cash / Debt
Q3 2023 · Cash: $12.4BQ3 2023 · Debt: $25.2BQ4 2023 · Cash: $13.4BQ4 2023 · Debt: $26.3BQ1 2024 · Cash: $9.5BQ1 2024 · Debt: $27.3BQ2 2024 · Cash: $7.9BQ2 2024 · Debt: $29BQ3 2024 · Cash: $13.6BQ3 2024 · Debt: $32.2BQ4 2024 · Cash: $11.5BQ4 2024 · Debt: $31.3BQ1 2025 · Cash: $7.1BQ1 2025 · Debt: $31.3BQ2 2025 · Cash: $6.7BQ2 2025 · Debt: $32.6BQ3 2025 · Cash: $9.6BQ3 2025 · Debt: $32BQ4 2025 · Cash: $11.4BQ4 2025 · Debt: $37.1BQ1 2026 · Cash: $6.9BQ1 2026 · Debt: $47BQ2 2026 · Cash: $7.6BQ2 2026 · Debt: $49BQ3 2023Q2 2026
CashDebt
Profitability
Q3 2023 · Gross margin: +74.2%Q4 2023 · Gross margin: +74.3%Q1 2024 · Gross margin: +74.5%Q2 2024 · Gross margin: +75.3%Q3 2024 · Gross margin: +75.4%Q4 2024 · Gross margin: +75.5%Q1 2025 · Gross margin: +76.3%Q2 2025 · Gross margin: +77.6%Q3 2025 · Gross margin: +75.4%Q4 2025 · Gross margin: +73.4%Q1 2026 · Gross margin: +74.4%Q2 2026 · Gross margin: +74.5%Q3 2023 · Operating margin: +14.6%Q4 2023 · Operating margin: +21.9%Q1 2024 · Operating margin: +27.8%Q2 2024 · Operating margin: +31.2%Q3 2024 · Operating margin: +27.5%Q4 2024 · Operating margin: +26.0%Q1 2025 · Operating margin: +34.2%Q2 2025 · Operating margin: +32.8%Q3 2025 · Operating margin: +31.3%Q4 2025 · Operating margin: +26.4%Q1 2026 · Operating margin: +31.3%Q2 2026 · Operating margin: +32.8%Q3 2023 · Net margin: +14.6%Q4 2023 · Net margin: +72.0%Q1 2024 · Net margin: +22.2%Q2 2024 · Net margin: +25.2%Q3 2024 · Net margin: +24.2%Q4 2024 · Net margin: +20.8%Q1 2025 · Net margin: +26.5%Q2 2025 · Net margin: +27.2%Q3 2025 · Net margin: +27.4%Q4 2025 · Net margin: +18.1%Q1 2026 · Net margin: +23.3%Q2 2026 · Net margin: +22.7%Q3 2023Q2 2026
Gross marginOperating marginNet margin
Revenue growth
Q2 2024: +9.6%Q3 2024: +8.9%Q4 2024: +15.1%Q1 2025: +12.4%Q2 2025: +15.3%Q3 2025: +9.0%Q4 2025: -1.6%Q1 2026: -0.7%Q2 2026: -2.8%Q3 2023Q2 2026
Shares outstanding
Q3 2023: 2.1BQ4 2023: 2.1BQ1 2024: 2.1BQ2 2024: 2BQ3 2024: 2BQ4 2024: 2BQ1 2025: 2BQ2 2025: 2BQ3 2025: 1.9BQ4 2025: 1.9BQ1 2026: 1.9BQ2 2026: 1.9BQ3 2023Q2 2026
Valuation
Q3 2023 · P/E: 28.4Q4 2023 · P/E: 6.1Q1 2024 · P/E: 18.2Q2 2024 · P/E: 16.6Q3 2024 · P/E: 18.2Q4 2024 · P/E: 17.1Q1 2025 · P/E: 15.2Q2 2025 · P/E: 14.6Q3 2025 · P/E: 15.2Q4 2025 · P/E: 27.4Q1 2026 · P/E: 23.1Q2 2026 · P/E: 22.9Q3 2023 · P/S: 16.4Q4 2023 · P/S: 17.6Q1 2024 · P/S: 16.2Q2 2024 · P/S: 16.8Q3 2024 · P/S: 17.6Q4 2024 · P/S: 14.3Q1 2025 · P/S: 16.1Q2 2025 · P/S: 15.9Q3 2025 · P/S: 16.6Q4 2025 · P/S: 19.8Q1 2026 · P/S: 21.6Q2 2026 · P/S: 20.7Q3 2023Q2 2026
P/EP/S
Revenue
2018: $46.1B2019: $48.7B2020: $49.9B2021: $44B2022: $43.5B2023: $46.7B2024: $51.7B2025: $54.8B20182025
Net income
2018: $12.6B2019: $11.7B2020: $8.1B2021: $24B2022: $7B2023: $14.9B2024: $11.9B2025: $14.1B20182025
EBITDA
2018: $20.2B2019: $15.6B2020: $17.2B2021: $30.9B2022: $14.7B2023: $18.3B2024: $20.7B2025: $23B20182025
Free cash flow
2018: $10.9B2019: $11.4B2020: $11.1B2021: $12.5B2022: $12B2023: $11.7B2024: $13.8B2025: $17.7B20182025
EPS
2018: $5.382019: $3.082020: $3.522021: $10.62022: $3.172023: $7.12024: $5.872025: $7.1920182025
Cash / Debt
2018 · Cash: $13.3B2018 · Debt: $32.1B2019 · Cash: $11.1B2019 · Debt: $29.1B2020 · Cash: $9.7B2020 · Debt: $37.9B2021 · Cash: $12.4B2021 · Debt: $31B2022 · Cash: $7.5B2022 · Debt: $27.9B2023 · Cash: $13.4B2023 · Debt: $26.3B2024 · Cash: $11.5B2024 · Debt: $31.3B2025 · Cash: $11.4B2025 · Debt: $37B20182025
CashDebt
Profitability
2018 · Gross margin: +68.5%2019 · Gross margin: +70.4%2020 · Gross margin: +69.7%2021 · Gross margin: +73.3%2022 · Gross margin: +73.4%2023 · Gross margin: +73.3%2024 · Gross margin: +75.2%2025 · Gross margin: +75.0%2018 · Operating margin: +18.2%2019 · Operating margin: +18.7%2020 · Operating margin: +20.3%2021 · Operating margin: +22.9%2022 · Operating margin: +18.3%2023 · Operating margin: +20.9%2024 · Operating margin: +28.1%2025 · Operating margin: +31.2%2018 · Net margin: +27.4%2019 · Net margin: +24.1%2020 · Net margin: +16.2%2021 · Net margin: +54.6%2022 · Net margin: +16.0%2023 · Net margin: +31.8%2024 · Net margin: +23.1%2025 · Net margin: +25.6%20182025
Gross marginOperating marginNet margin
Revenue growth
2019: +5.6%2020: +2.5%2021: -11.9%2022: -1.2%2023: +7.4%2024: +10.8%2025: +6.0%20182025
Shares outstanding
2018: 2.3B2019: 2.3B2020: 2.3B2021: 2.3B2022: 2.2B2023: 2.1B2024: 2B2025: 2B20182025
Valuation
2018 · P/E: 13.22019 · P/E: 28.72020 · P/E: 25.22021 · P/E: 7.72022 · P/E: 26.92023 · P/E: 14.12024 · P/E: 16.42025 · P/E: 19.02018 · P/S: 3.62019 · P/S: 4.22020 · P/S: 4.12021 · P/S: 4.22022 · P/S: 4.32023 · P/S: 4.52024 · P/S: 3.82025 · P/S: 4.920182025
P/EP/S

Refreshed 5h ago

Next catalyst

Catalysts

Earnings
2026-10-27
Revenue est. $14.6B · Updated 5h ago
Dividend
$4.74
2026-03-11

No unusual perp activity right now.

Research data

Analysts, filings and peer context

Estimates

6
DateEPS estimateRevenue estimateGrowthAnalysts
FY 20268.77$57.1B+4%7
FY 20279.79$60.9B+11%8
FY 202810.81$65.1B+19%6
FY 202911.86$68.3B+25%5
FY 203013.20$71.7B+31%5
Q2 20262.17$14.1B-5%3

Company events

6
2026-10-27EarningsActual - / Estimate 2.24-
2026-07-21EarningsActual 2.41 / Estimate 2.17Beat
2026-04-28EarningsActual 1.99 / Estimate 2.11Miss
2026-03-11Dividend$4.74-
2026-02-04EarningsActual 2.03 / Estimate 1.99Beat
2025-10-28EarningsActual 2.25 / Estimate 2.26Miss

Peer comparison

Similar listed perps

FMP company data

Company intelligence

Updated: Sep 4, 2026, 09:51 AM UTC

Company profile

Sector
Healthcare
Industry
Drug Manufacturers - General
Chief executive
Vasant Narasimhan
Employees
75,267
IPO date
Nov 7, 1996
Country
CH
Exchange
New York Stock Exchange
Website
Altman Z-scorei3.65
Piotroski scorei6/9
FMP ratingiB+
Owner earningsi$5.46B$2.85 per share
ESG risk ratingiB+Industry rank: 11 out of 27

Rating factors

Return on equityi
5
Return on assetsi
5
Debt to equityi
1
Price to earningsi
2
Price to booki
1
Market cap history
2026-06-032026-09-03Latest: $310.10BHigh: $310.10BLow: $274.25B
Largest fund holders
FundWeightShares held
VPMAX0.69%4.3M
FLCB0.05%1.6M
FLCO0.22%1.3M
VHCAX0.58%1.2M
BTMKX1.29%1.2M
DFIV0.63%888.9K
DFAI0.65%765.2K
DFIC0.72%720.5K
VPCCX0.58%669.8K
AVDE0.54%666.9K
PPH10.05%666.8K
DIHP1.38%587.9K

Next step

Stay on top of NVS perps

Weekly digest by email

The listings, funding and moves that matter for NVS — one email every Sunday.

Watchlist and alerts

Price and funding alerts for NVS, via push or Telegram.

Set an alert

Follow the live feed

Daily movers, new listings and funding extremes as they happen.

Follow on X

Frequently asked questions

Where can I trade NVS perpetual futures?

Novartis AG (NVS) perpetual futures trade on 1 crypto venues, including Bitget. PerpEquities compares them by live price, funding rate, open interest and liquidity.

Can I trade NVS around the clock?

Yes. Unlike the underlying stock, NVS perpetuals trade 24/7 — including weekends and outside regular market hours.

What is the funding rate on NVS perpetuals?

Right now the NVS perp funding rate is 0.0% annualized (venue median), ranging from 0.0% to 0.0% across 1 venues. A positive rate means longs pay shorts. PerpEquities shows the live rate and its history for every venue.

How does the NVS perp price compare to the Novartis AG stock?

The venue-median NVS perp mark is $160.4 versus a reference stock price of $160.4, a basis of 0.0%. Perps follow the stock through an index price; the gap widens when funding or liquidity diverge between venues.

What is a NVS perpetual future?

A NVS perpetual is a derivative that tracks the price of Novartis AG with no expiry date. It lets you take long or short exposure to Novartis AG on crypto venues, around the clock.

What is NVSUSDT perpetual?

NVSUSDT is the symbol most crypto exchanges use for the Novartis AG perpetual settled in USDT (Tether). It tracks the NVS share price through an index, trades 24/7 with leverage and never expires.